Bispecific monoclonal antibody

Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D

Retrieved on: 
Monday, August 20, 2018
Medicine, Biology, Health, Immunology, Immune system, Monoclonal antibodies, Biotechnology, Biopharmaceutical, Pharmaceutical industry, Bispecific monoclonal antibody, Cancer immunotherapy, Antibody

Aptevo will use the Genedata Biologics platform to facilitate expansion of their pipeline of novel bispecific antibody candidates focused on immuno-oncology, autoimmune disease and inflammation.

Key Points: 
  • Aptevo will use the Genedata Biologics platform to facilitate expansion of their pipeline of novel bispecific antibody candidates focused on immuno-oncology, autoimmune disease and inflammation.
  • "We appreciate Genedata Biologics' flexible business model, which made it possible for a company of our size to adopt a market-leading platform solution," said William Benjamin, IT Director at Aptevo.
  • "As an established, off-the-shelf product, Genedata Biologics could be deployed across our organization with minimal customization.
  • On August 21 at 11:20 EDT, Genedata Biologics will be featured at the Bispecific Antibody Pipeline Congress in the presentation "Bispecific Platform Designed for Rapid Development and Manufacturing of Novel Protein Therapeutics" by Peter Pavlik, PhD, Principle Scientist, Aptevo Therapeutics.

GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination With a Multi-Billion Dollar Oncology Drug

Retrieved on: 
Thursday, July 19, 2018
Medicine, Monoclonal antibodies, Immunology, Clinical medicine, Immune system, Health, Bispecific monoclonal antibody, Antibody

Dr. Vallera is the lead researcher for GT Biopharma's bispecific antibody drug conjugate (ADC) program, and the innovator of oncology drug candidate DT2219, also known as OXS-1550.

Key Points: 
  • Dr. Vallera is the lead researcher for GT Biopharma's bispecific antibody drug conjugate (ADC) program, and the innovator of oncology drug candidate DT2219, also known as OXS-1550.
  • OXS-1550 targets two antigens on cancer cells and contains a cytotoxic payload thereby increasing the probability it will kill the cancer cells.
  • Initial pre-clinical work performed by Dr. Vallera suggests a much greater effect when OXS-1550 is given in combination with this established oncology drug.
  • GT Biopharma, Inc. is a biotechnology company focused on innovative drugs for the treatment of cancer.

Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting

Retrieved on: 
Friday, May 25, 2018
Medicine, Immunology, Immune system, Monoclonal antibodies, Clinical medicine, Antibody, Glycoproteins, Asco, Cancer immunotherapy, Bispecific monoclonal antibody

These presentations include preclinical and translational data on GBR 1302, a HER2xCD3 bispecific antibody, and a Trials in Progress (TIP) poster on GBR 1342, a CD38xCD3 bispecific antibody.

Key Points: 
  • These presentations include preclinical and translational data on GBR 1302, a HER2xCD3 bispecific antibody, and a Trials in Progress (TIP) poster on GBR 1342, a CD38xCD3 bispecific antibody.
  • Enrollment for the GBR 1302 clinical trial is currently ongoing in the U.S. and Germany.
  • "We are pleased to share these emerging data and updates on our immuno-oncology pipeline at the ASCO Annual Meeting."
  • Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years.

Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting

Retrieved on: 
Wednesday, April 18, 2018
Medicine, Immunology, Monoclonal antibodies, Biology, Health, Immune system, Bi-specific T-cell engager, Tumor microenvironment, Antibody, Natural killer cell, Bispecific monoclonal antibody

Data show that the engineered complex enhanced the duration and magnitude of T and NK cell proliferation in vitro and in vivo.

Key Points: 
  • Data show that the engineered complex enhanced the duration and magnitude of T and NK cell proliferation in vitro and in vivo.
  • XmAb24306 is designed for reduced potency and extended half-life, and exhibited a steady, tolerable and sustained increase in T-cells in primates.
  • XmAb24306 is the first of a suite of tumor microenvironment activators using the IL15 bispecific platform.
  • Additional IL15 bispecific candidates, which target specific sub-populations of T cells, in preclinical development include:
    Xencor's XmAb IL15 bispecific antibody platform provides a more druggable version of IL15 with reduced potency to improve tolerability, slow receptor-mediated clearance, and prolong half-life.